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letters to the editor
The following is an abstract of the article discussed in
the subsequent letter:
Finegood, Diane T., and Dan Tzur. Reduced glucose
effectiveness associated with reduced insulin release: an
artifact of the minimal-model method. Am. J. Physiol. 271
(Endocrinol. Metab. 34): E485–E495, 1996.—We previously
demonstrated that minimal model-derived estimates of glu-
cose effectiveness (SG), based on the frequently sampled
intravenous glucose tolerance test (SGFSIGT), were reduced in
islet-transplanted or streptozotocin-treated dogs and in pa-
tients with insulin-dependent diabetes mellitus. To ascertain
the validity of our observations, we compared SGFSIGT with
estimates based on a basal hormone replacement glucose
clamp (SGBRCLAMP) and a basal hormone replacement glucose
tolerance test (SGBRGTT) in normal control (CNTL, n 5 12) and
streptozotocin-treated dogs with normal fasting plasma glu-
cose (STZ-Rx, n 5 9). SGFSIGT was reduced in STZ-Rx com-
pared with CNTL (P , 0.05). However, neither SGBRCLAMP nor
SGBRGTT was reduced in the STZ-Rx group (P . 0.05). Compari-
son of protocols for each subject indicated that SGFSIGT was
greater than either SGBRCLAMP or SGBRGTT in control (P , 0.002)
but not in STZ-Rx dogs (P . 0.1). The relationship of SGFSIGT
to insulin secretory function suggests that our previous
conclusion that SGFSIGT was reduced in subjects with limited
insulin release may be an artifact of the minimal-model
method. Our results suggest that caution must be exercised
in the interpretation of differences in minimal-model esti-
mates of SG between subject groups with significantly differ-
ent levels of insulin secretory function.
Minimal Model Estimate of Glucose Effectiveness:
Role of the Minimal Model Volume and of
the Second Hidden Compartment
To the Editor: The paper by Finegood and Tzur (9) on a
potential artifact of the minimal model (3) in assessing
glucose effectiveness addresses a relevant issue given
the important role of this index (1, 2, 5). In reading
their arguments, we think that some clarification of
some of their methodological aspects of data analysis
and some of their conclusions would be helpful for other
readers. We think that our observations and insights
are critical, especially in light of the increasing demand
for a better definition of the domain of validity of the
minimal model estimate of glucose effectiveness called
for by recent experimental (10) and theoretical (6–8)
results.
The volume issue. Comparison of the minimal model
index of glucose effectiveness, SGFSIVGTT, measured from
a frequently sampled intravenous glucose tolerance
test, FSIVGTT, with the analogous clamp-based index,
SGBRCLAMP, measured from a basal hormone replace-
ment glucose clamp, BRCLAMP, requires coping with
the fact that the two indexes are not expressed in the
same units. Whereas SGFSIVGTT, a fractional index, is
expressed in minutes, SGBRCLAMP is expressed in millili-
ters per kilogram per minute. To convert the two
indexes to common units, one must either multiply
SGFSIVGTT or divide SGBRCLAMP by some volume factor.
Various approaches have been taken. Ader et al. (1)
divided the mean value of SGBRCLAMP by Steele’s volume
(169 ml/kg) (12). In contrast, Finegood and Tzur (9)
chose to divide SGBRCLAMP by the mean total volume of
glucose distribution taken from the literature (250
ml/kg). However, as Finegood and Tzur state in their
paper, ‘‘the approach taken and the (volume) estimate
used will affect the magnitude of SGBRCLAMP and could
impact on the conclusion that SG is overestimated by
the minimal model method in normal subjects.’’ More-
over, it is important to recognize that the chosen
approach and volume are likely to affect their correla-
tion plots (Figs. 4 and 5 in Ref. 9) between SGFSIVGTT,
SGBRCLAMP, and the third index of glucose effectiveness
they measured, SGBRGTT, based on a basal hormone
replacement glucose tolerance test, BRGTT.
The resolution of the volume issue is thus of para-
mount importance to put the comparison between
minimal model and clamp indexes of glucose effective-
ness on firm ground. In a previous paper (6) we
suggested that to convert the minimal model and clamp
indexes to the same units one should multiply SGFSIVGTT
by the minimal model volume of glucose distribution, V,
because the information leading to an individualized
estimate of the volume is available in each FSIVGTT
data set. We will show formally that this is the correct
approach. To do so we need to return to the definition of
glucose effectiveness. Glucose effectiveness measures
the effect of glucose at basal insulin to enhance its own
disappearance from plasma (Rd) and inhibit its own
endogenous production (EGP) (5)
Glucose effectiveness 5
d[Rd(t) 2 EGP(t)]
dG(t) 0I 5 Ib (1)
where Ib denotes basal insulin concentration. Applying
the above definition to a glucose clamp in which one
attains a steady state for plasma glucose concentration,
Rd, and EGP, one has
Clamp glucose effectiveness 5
D[Rd 2 EGP]
DG
5
GINF
DG
5 SGBRCLAMP(ml?kg21 ?min21)
(2)
where GINF is the exogenous glucose infusion rate
needed to compensate for the increase in Rd and the
decrease in EGP.
The minimal model describes glucose dynamics dur-
ing an intravenous glucose tolerance test with the
well-known equations
dG(t)
dt
5 2[SG 1 X(t)]G(t) 1 SGGb G(0) 5 Gb 1
D
V
dX(t)
dt
5 2p2[X(t) 1 SI(I(t) 2 Ib)] X(0) 5 0
(3)
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where D is the injected glucose dose and V is the
minimal model volume of glucose distribution. The
index of glucose effectiveness, SG, will denote SGFSIVGTT
or SGBRGTT, depending on whether a FSIVGTT or a
BRGTT is carried out. Of note is that during a BRGTT
insulin action X in Eq. 3 is identically equal to zero. If
we express the glucose equation in terms of glucose
mass instead of concentration, its right member de-
scribes the net balance between Rd and EGP
Rd(t) 2 EGP(t) 5 [SG 1 X(t)]Q(t) 2 SGQb
Q(t) 5 G(t)V
(4)
where Q is the glucose mass in the system. Applying the
definition of glucose effectiveness (Eq. 1) to the expres-
sion of Rd-EGP of the minimal model given by Eq. 4, one
obtains
Minimal model glucose effectiveness 5 SGV
(ml ?kg21 ?min21)
(5)
Comparing Eqs. 2 and 5, one can see that no conversion
is necessary because the minimal model method pro-
vides an index of glucose effectiveness that has the
same units as the clamp-based index. Of note is that V
can be estimated from the same data that provide
SGFSIVGTT or SGBRGTT and can therefore be individual-
ized in each subject. Because the volume information is
contained in the data, the use instead of Steele’s volume
[as in Ader et al. (1)] or of a mean total glucose
distribution volume [as in Finegood and Tzur (9)] is
hardly justifiable. Incidentally, this individualized vol-
ume has been already used in the validation studies of
the minimal model insulin sensitivity index, where SIV
has been evaluated against the insulin sensitivity
index measured by the clamp technique (3, 11).
In light of the above considerations, the question
arises as to whether the conclusions drawn in Ref. 9 are
confirmed if an individualized volume is used instead of
the mean total distribution volume. Specifically, two
points need to be readdressed.
SGFSIVGTT vs. SGBRGTT. Finegood and Tzur found that,
in normal subjects, the fractional glucose effectiveness
index measured during a traditional FSIVGTT,
SGFSIVGTT, is higher than the one estimated during a
glucose tolerance test at basal insulin, SGBRGTT. Does
this relationship still hold when each fractional index is
multiplied by the companion volume V? The question
arises because in all likelihood the minimal model
volume V estimated from a FSIGT is lower than that
estimated from a BRGTT.
Noncorrelation between SGBRGTT and SGBRCLAMP. The
noncorrelation (r 5 0.05) between SG BRGTT and
SGBRCLAMP of Fig. 5 in Ref. 9 is quite a surprise and
would have deserved more discussion in the paper. This
result implies that, even at basal insulin, i.e. under
optimized experimental conditions, the minimal model
does not provide a valid measure of glucose effective-
ness. Of the two measures of glucose effectiveness
SGBRCLAMP has more history, so let’s assume for the sake
of reasoning that SGBRCLAMP is not a problem. In calcu-
lating glucose effectiveness from the BRGTT, what’s
still missing is the volume V estimated in each indi-
vidual. Thus the correlation between the BRGTT- and
BRCLAMP-based indexes of glucose effectiveness needs
to be reevaluated by comparing SGBRCLAMP to SGBRGTTV.
Role of the hidden compartment. Finegood and Tzur
found that SGFSIVGTT is higher than SGBRGTT in normal
dogs but not in dogs with reduced insulin secretory
function. The result obtained in normal dogs is in
keeping with the results reported by Quon et al. (10),
who found in insulin-dependent diabetic patients a
discrepancy between the minimal model prediction and
the experimentally observed profile of glucose concen-
tration during a BRGTT. Finegood and Tzur formu-
lated the hypothesis that, when the minimal model is
applied to individuals with a normal insulin secretory
function, it is unable to correctly segregate glucose and
insulin effects on glucose disappearance. This is an
elegant way of putting the issue, but it does not help
much in clarifying what’s wrong with the minimal
model.
The finding that SGFSIVGTT is higher than SGBRGTT in
normal dogs is clearly a symptom of model error,
because the value that is taken on by SG should be
independent of the insulin profile during the glucose
tolerance test. So where is the error in the minimal
model? Finegood and Tzur did not answer this ques-
tion. Here we would like to offer our interpretation of
their findings by building on a recent paper in which we
theoretically analyzed the effect of the single-compart-
ment approximation of the minimal model on SG estima-
tion by using a two-compartment model as a reference
(7). First, Finegood and Tzur showed that glucose decay
during a BRGTT is biexponential and not monoexponen-
tial as dictated by the minimal model, thus confirming
our theoretical prediction (7). They then concluded that
the monocompartmental description of glucose kinetics
is sufficiently adequate, since the minimal model was
well able to describe the BRGTT glucose data from 10
min onward. Unfortunately, the finding that the single-
pool description is reasonably good when the glucose
system is studied at basal insulin does not ensure that
such an approximation is also adequate when insulin,
in addition to glucose, changes during the test. Extrapo-
lating to the FSIVGTT what has been found with the
BRGTT is not only methodologically questionable but
probably fallacious. During the BRGTT glucose decay
is governed only by glucose effectiveness, and SG is
estimated from the whole glucose data set between 10
and 180 min. Because the fast component of glucose
disappearance becomes negligible after ,20 min,
SGBRGTT is mainly determined by the slow component.
In contrast, during the FSIVGTT, glucose decay reflects
both glucose effectiveness and insulin sensitivity, and
SG is mainly estimated in the initial portion of the test,
when glucose is high and insulin action, albeit increas-
ing, is low. Because this is the moment when the fast
component of glucose disappearance plays the major
role (7), it is easy to realize that one will obtain higher
values of SGFSIVGTT than SGBRGTT. In other words, we
speculate that the monocompartmental approximation
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is much more critical during the FSIVGTT than during
the BRGTT, and the higher values observed for SGFSIVGTT
than for SGBRGTT can be explained by the presence of a
second, inaccessible compartment. The finding that the
gap between SGFSIVGTT and SGBRGTT is reduced in ani-
mals with impaired secretory function also fits with the
above reasoning: when the early insulin response is
absent, the time window crucial for SG estimation
(glucose high and insulin action low) widens, and the
relative importance of the fast vs. the slow component
of Rd in determining the value of SG diminishes. As a
result, SGFSIVGTT comes close to the value of the slow
component and thus to SGBRGTT.
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REPLY
To the Editor: Drs. Caumo and Cobelli have raised
several issues with regard to our 1996 publication on
artifacts in minimal model-derived glucose effective-
ness (3). We appreciate this opportunity to expand on
explanations given in our 1996 paper. Caumo and
Cobelli raise two issues and consider them indepen-
dently: 1) the means by which we corrected for the
volume of distribution and 2) the two-compartment
nature of glucose kinetics. These two issues are not
independent. If, as they argue in the second part of
their letter, a second compartment is responsible for
the observed artifact, then it is not consistent to
assume that a single time-invariant volume of distribu-
tion, estimated from the initial slope of glucose fall
during an intravenous glucose tolerance test, is the
best way to put clamp and frequently sampled intrave-
nous glucose tolerance (FSIGT) data on the same unit
basis.
The correspondents argue that it is more correct to
multiply SGFSIGT estimates by the initial distribution
volume than to divide the clamp-based estimate,
SGBRCLAMP, by a steady-state glucose distribution vol-
ume. Their argument is based on the fact that an
individualized volume of distribution can be obtained
from each FSIGT experiment and a tautological manipu-
lation of the one-compartment glucose kinetics equa-
tion. Although we agree that it would be helpful to be
able to use a volume of distribution that is based on
each individual subject’s data, we reject the notion that
this is theoretically more correct. Furthermore, we
believe this approach is not optimal because of the
so-called ‘‘hidden compartment.’’
Caumo and Cobelli perform some algebraic manipu-
lations, which they provide as proof that minimal-
model glucose effectiveness must be calculated as SGV.
In their manipulations, the distribution volume comes
up on the right side of the equation because their
starting definition of glucose effectiveness lacks consid-
eration of the distribution volume and is, in fact,
different from the original definition put forth by
Bergman et al. (1), including Dr. Cobelli. In the original
minimal-model paper, SG was defined as
SGFSIGT 5
dG˙
dG 0 I5Ib (1)
If we start with the basic mass balance equation
governing both the clamp and the FSIGT situation, we
have
EGP(t) 2 Rd(t) 1 GINF(t) 5
d[VG(t)]
dt
(2)
Because it has been assumed both by ourselves and by
Caumo and Cobelli that, in this instance, the hidden
compartment is not important and that the volume of
distribution is time invariant, this equation is equiva-
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lent to
EGP(t) 2 Rd(t) 1 GINF(t) 5 V
dG(t)
dt
(3)
In an FSIGT, GINF(t) 5 0, so
d[EGP(t) 2 Rd(t)]
dG
5 V
dG˙
dG
(4)
Combining Eqs. 1 and 4
SGFSIGT 5
1
V
d[Rd(t) 2 EGP(t)]
dG 0 I5Ib (5)
As Caumo and Cobelli have stated, clamp glucose
effectiveness is defined as
SGBRCLAMP 5
D(Rd 2 EGP)
DG
(6)
Combining Eqs. 5 and 6, we have
SGFSIGT 5
1
V
SGBRCLAMP (7)
or the equivalent expression
SGBRCLAMP 5 SGFSIGT 3 V (8)
Clearly the result of this algebraic manipulation
depends on your starting point, and from a theoretical
point of view both equations are correct. The form of the
equation that first emerges is determined by whether
you start with the original definition of glucose effective-
ness or with a definition that lacks consideration of the
distribution volume.
Given that true glucose kinetics are approximated
only by a single compartment and that a second so-
called hidden compartment may be important, we must
also consider the effect of the hidden compartment on
estimates of the distribution volume. Wolfe (5) clearly
demonstrated that, in the nonsteady state, a single-
compartment volume of distribution varies with time,
with the greatest time dependence occurring at the
beginning of a perturbation such as glucose administra-
tion. In contrast, as the system approaches steady
state, the distribution volume varies less in time and
approximates the original value determined by Steele
at 25% of body weight (4). For this reason, we believe
the nonindividualized steady-state estimate of distribu-
tion volume used to correct the clamp calculation may
be more accurate than the individualized, but highly
time-dependent estimate of the initial distribution
volume obtained during the FSIGT. Because the as-
sumption that the distribution volume does not vary is
incorporated in the definition of glucose effectiveness,
we believe use of the steady-state estimate to correct
the steady-state experiment is less subject to error.
The correspondents suggest that, if we correct SGFSIGT
and SGBRGTT by the individual estimates of the distribu-
tion volume, these two parameters will become equiva-
lent, because they believe that the volume estimated
from an FSIGT will be lower than that estimated from a
BRGTT. The reason why they believe that the volume
estimated from the FSIGT would be lower than that
from the BRGTT was not explained. Contrary to their
expectations, the distribution volume estimates from
these two types of experiments are identical (1.32 6 0.13
vs. 1.31 6 0.13 dl/kg, P 5 0.89 by paired t-test), and the
relationship between SGBRGTT 3 V and SGFSIGT 3 V is
the same as in Fig. 4B of our original manuscript (3).
Drs. Caumo and Cobelli also speculated that if we
correct SGBRGTT rather than SGBRCLAMP, the correlation
in Fig. 5 might improve. In fact, SGBRGTT 3 V is also not
correlated with SGBRCLAMP (r 5 0.28, P 5 0.43), and the
previously equivalent estimates of glucose effectiveness
are no longer equivalent (SG BRGTT 5 1.9 6 0.2 vs.
SGBRCLAMP 5 4.3 6 0.5 ml·min21 ·kg21, P , 0.001). We
take this as further proof that correction of SGBRCLAMP is
more appropriate than that of SGBRGTT or SGFSIGT with
individualized values of the distribution volume. The
lack of correlation between SGBRCLAMP and SGBRGTT is
more likely due to the rather small (,3-fold) range of
normal values and the fact that the estimate of
SGBRCLAMP is not very precise. As we indicated in our
paper (3), the coefficient of variation for SGBRCLAMP was
60 6 15%. Although the coefficient of variation for
SGBRGTT was not determined, we expect that it would be
similar to that of SGFSIGT, which was found to be
23 6 4%.
Finally, we agree with the correspondents that their
subsequent model-based analysis (2) of the role of the
hidden compartment helps to explain the reason for the
artifact identified in our paper (3). Their arguments
provide a theoretical basis for our contention that the
inadequacy of the one-compartment representation of
the BRGTT experiments in control animals but not in
streptozotocin-treated animals might provide at least a
partial explanation for the observed artifact. The corre-
spondents’ demonstration that the hidden compart-
ment is important (2) was beyond the scope of our
original paper (3).
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